Biotechnology
Journal
DOI 10.1002/biot.201200226
Biotechnol. J. 2012, 7, 1522–1529
Perspective
How can measurement, monitoring, modeling and control
advance cell culture in industrial biotechnology?
Manuel J. T. Carrondo1,2, Paula M. Alves1,2, Nuno Carinhas1,2, Jarka Glassey3, Friedemann Hesse4,
Otto-Wilhelm Merten5, Martina Micheletti6, Thomas Noll7, Rui Oliveira1,8, Udo Reichl9, Arne Staby10,
Ana P. Teixeira1,2, Henry Weichert11 and Carl-Fredrik Mandenius12
11 Instituto
de Biologia Experimental e Tecnológica (IBET), Oeiras, Portugal
de Tecnologia Química e Bioquímica (ITQB), Universidade Nova de Lisboa, Oeiras, Portugal
13 Newcastle University, Newcastle upon Tyne, UK
14 University of Applied Sciences, Biberach, Germany
15 Généthon, Evry, France
16 University College London, London, UK
17 University of Bielefeld, Bielefeld, Germany
18 Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal
19 Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
10 Novo Nordisk A/S, Gentofte, Denmark and Lund University, Lund, Sweden
11 Sartorius Stedim Biotech GmbH, Göttingen, Germany
12 Linköping University, Linköping, Sweden
12 Instituto
This report highlights the potential of measurement, monitoring, modeling and control (M3C)
methodologies in animal and human cell culture technology. In particular, state-of-the-art of M3C
technologies and their industrial relevance of existing technology are addressed. It is a summary
of an expert panel discussion between biotechnologists and biochemical engineers with both
academic and industrial backgrounds. The latest ascents in M3C are discussed from a cell culture
perspective for industrial process development and production needs. The report concludes with
a set of recommendations for targeting M3C research toward the industrial interests. These include
issues of importance for biotherapeutics production, miniaturization of measurement techniques
and modeling methods.
Received 15 JUN 2012
Revised 10 JUL 2012
Accepted 31 JUL 2012
Keywords: Biopharmaceuticals · Gene therapy · Mammalian cells · Stem cells · Viral vectors
1 Purpose and background
Cell culture technology involves a wide range of cell types:
insect, avian, rodent, primate, and human cells/cell lines,
as well as embryonic, induced pluripotent, and adult stem
cells. Their applications in industrial processes include
Correspondence: Prof. Carl-Fredrik Mandenius, Division of
Biotechnology/IFM, Linköping University, S-583 31 Linköping, Sweden
E-mail: cfm@ifm.liu.se
Abbreviations: CQA, critical quality attribute; M3C, measurement, monitoring, modeling and control; MVDA, multivariate data analysis; PAT, process
analytical technology; QbD, quality by design
1522
products such as therapeutic proteins, viruses for vaccination and gene therapy purposes, and cells per se
(Fig. 1).
Methods in measurement, monitoring, modeling, and
control (M3C) are critical for the production and characterization of biopharmaceuticals due to the complexity inherent in the host cells and molecules considered [1–4].
The success of and increasing use of animal cell culture
technologies in industry make M3C methodologies, especially for process design and optimization, an important
challenge both in the academic and industrial communities.
This expert panel report intends to address issues relevant to all of these applications for users of cell culture
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Biotechnol. J. 2012, 7, 1522–1529
www.biotecvisions.com
Figure 1. Main areas of cell culture applications where M3C methods are required.
technology. It focuses on mapping how the academic and
industrial competences in M3C can jointly target the development of better solutions for purposes outlined in
guidance documents [5–7] and, more broadly, by considering additional biotechnology manufacturing requirements.
2 The application of M3C methods in
the cell culture industry at present
M3C methods applied in industry at present have largely
been implemented to satisfy regulatory requirements but
the sales success of many biopharmaceuticals has also
driven industry to use M3C methods to facilitate improvements in process development times, process understanding, and to drive down cost of goods.
The International Conference on Harmonization (ICH)
quality Q1–Q11 guidelines [7] outline distinct recommendations for the pharmaceutical industry. This covers substantial parts of the measurement and monitoring
methodology concerning quality attributes such as prod-
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
uct identity, impurity levels, final product characteristics,
cell banking and validation of the analytical procedures,
sensors and equipment. It also clearly addresses the quality system and risk analysis aspects and, by that, adjoins
to efforts in realizing process analytical technology (PAT)
and quality by design (QbD) objectives [8, 9]. These
guidelines can also be taken as guidance and advice for
process analytical work in the non-pharmaceutical cell
culture industry. The needs for good quality in combination with process economy may drive technical development along the same routes even if the regulatory authorities are not the driving force.
Table 1 lists areas in industrial cell culture technology
where measurement, monitoring and, occasionally, modeling and control have significant impact. Examples of
such activities are cell line engineering and development,
plasmid transfection, stem cell differentiation and expansion, culture media optimization, bioprocess development and control, product recovery, quality control, and
QbD.
Currently, mainly pH, DO, and CO2 control loops are
applied although more on-line (e.g., glucose and lactate
1523
Biotechnology
Journal
Biotechnol. J. 2012, 7, 1522–1529
www.biotechnology-journal.com
Table 1. Typical cell culture activities requiring M3C methodologies
Cell culture activity
Examples of M3C methodology involved
Cell line engineering and development
Cell imaging
Glycosylation profiling
RT-PCR for mRNA expression analysis
Microarrays for transcriptome analysis
HPLC, NMR, GC-MS, LC-MS
On-line monitoring of bioreactor state variables (temp., pO2, pCO2, pH, agitation, redox,
conductivity)
On-line spectroscopic techniques (NIR, fluorescence)
Imaging, flow cytometry
Microarrays for mRNA expression
Glycoprotein profiling
Control of state variables and feeding
Mechanistic models of the bioreactor process
MVDA and mechanistic models of the bioreactor process
Biomarker measurement, expression arrays
Cell imaging, analysis of CQAs
Label-free protein quantification by absorption measurement
HPLC, Spectrometric analysis, pH, conductivity
Immunosensors, HPLC
Culture media optimization
Bioprocess development and control
Stem cell expansion and differentiation
Protein and vector recovery
Protein production purification
Product quality control
analyzer) or at-line (e.g., cell number estimation or on-line
gas analysis) monitoring techniques are being available.
Especially demanding measurement methods are found
in microscopical analysis and omics methods.
During cell line development M3C methods are largely restricted to product titer and cell growth analyses. Increasingly, methods to characterize some elements of
product quality are being applied at this early stage, particularly methods amenable to high-throughput screening. Once a manufacturing cell line has been identified,
production cell culture largely concentrate on pH, DO, and
CO2 control loops with at-line analyses of critical parameters such as cell number, viability, residual nutrient medium analysis (e.g., glucose, glutamine, lactate), and product titer if product is not the “cell” itself. In the relatively
new area of stem cell expansion and manufacture the focus is to understand and characterize, as far as current
methods allow any measurable impacts on cell phenotype, genotype, and any important epigenetic changes.
3 State of the art in M3C research and
its connection to industrial cell culture
technology
M3C research of relevance for cell culture technology does
also take place at small and large companies involved in
developing industrial measurement, instrumentation,
and control systems for non-biopharmaceutical products.
Indeed, the vast majority of M3C users are in industrial
sectors such as vehicle and aircraft manufacturing, the
electronics, machining and food industry, mining, med-
1524
ical technology, etc. Commercial M3C related products
have significantly larger volumes in those areas than in
biotechnology, making it likely that new valuable M3C
technologies may first be invented in a non-biotechnology environment as requirements and boundary conditions for research, such as state-of-the-art of technology
and instrument development cost, are often the same.
Research and development of biotherapeutics is a
complex and time-consuming process requiring significant effort and investment. Significant improvements in
cell line and process development have been implemented by exploiting a range of high-throughput methodologies though exploitation of broader or novel M3C technologies has been slow.
Nevertheless, the qualified research driven by industry’s needs ongoing in biotechnology-related M3C should
be supported, recognized, and valued. Research should
be separated into those M3C methods with potential to
impact on process development times, process robustness, process understanding, scale-up, and validation
versus M3C methods of monitoring (and controlling) the
manufacturing process itself during routine operation.
Basic M3C methods for measurement of bioprocess
state variables, such as electrochemical electrodes, optical probes, spectroscopic methods, and biosensors are
useful in cell culture processes and have been described
in detail previously [1–3].
Examples of M3C methods of particular interest for future application in cell culture processes which have recently undergone notable technological progress are
compiled in Table 2 [10–31].
Specific developments include measurement methods based on cDNA microarrays, glycan profile analysis,
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Biotechnol. J. 2012, 7, 1522–1529
www.biotecvisions.com
Table 2. Examples of recent research activities in M3C with high relevance for cell culture technology
M3C area
Research
Measurement
Microscopical imaging of cells for characterization purposes
Omics platforms for characterization
Flow cytometry analysis of vaccine production processes
Biomarkers in stem cell expansion and differentiation
Glycosylation profile analysis
Metabolome analysis
Downstream processing characterization
Multisensor array technologies, e.g. electronic noses and tongues
Monitoring of main effluent gases (O2, CO2)
Flow cytometry on-line
On-line multi-wavelength fluorimetry
NIR/MIR spectroscopy
Soft sensor modeling (combined with on-line sensing)
Hybrid models based on metabolic data
Metabolic flux analysis modeling for process control
Quality by design models for quality attributes
Mechanistic modeling of chromatography
Growth rate control
Stem cell bioreactor control
On-line
monitoring
Modeling
Control
Referencesa)
[10, 11]
[12, 13]
[14]
[15]
[16]
[17, 18]
[19]
[20, 21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[22]
[31]
a) References are either recent reviews or selected/representative applications.
and NMR or MS for metabolome analysis. Examples of
methods useful for on-line/at-line monitoring of cell cultures include multi-way fluorescence spectroscopy, electronic noses for contaminations and cell concentration,
and in situ near infrared and Raman spectroscopy probes
for medium components and viability.
Examples of modeling methods include mechanistic,
hybrid, and metabolic flux analysis approaches. In this
context, recent research efforts in the field of multivariate
data analysis (MVDA) should also be highlighted and
strengthened.
Measurement or monitoring methods for stem cell
processes where the purpose is the control of cell expansion and differentiation have not yet been defined with
few exceptions [15, 32], but progress with M3C methods
for, e.g., toxicity testing might be relevant in this field.
The same is valid for gene therapy production processes.
Several of the examples mentioned in Table 2 are the
result of collaborations between academia and industry
and often from publically funded projects. No doubt, M3C
development work is also performed within companies.
However, to our knowledge there are no fundamentally
new undisclosed M3C methodologies within the industry
R&D.
4 What are the most prominent needs
for M3C in cell culture industry?
The needs to improve M3C in cell culture processes can
be categorized in several ways.
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Clearly, the requirements are both cell type and target
product dependent. In the process operation, medium
and cell line development phases, the list of needs can be
very extensive. The panel identified certain needs that are
more prominent (Table 3) and are commented on below.
For animal and mammalian cells, tools able to measure and monitor media components and their uptake
rates are of particular interest. These include monitoring
of starting materials as well as carbohydrates, amino
acids (at least at-line when cell growth is not well characterized due to different process history or clones used),
lipids, vitamins, and trace elements to evaluate whether
limitations occur. Of significant value would be on-line or
at-line monitoring of critical quality attributes (CQAs) to
ensure that these are within the accepted control ranges;
this is a particular challenge for lower titer processes.
Stem cell culture processes (from human embryonic
stem cells, hESC, and induced pluripotent stem cells,
iPSC), although more demanding, have similar M3C
needs. M3C methods used to support cell manufacturing
and cell-product release whether on-line or at line must
deliver information quickly given the short “shelf” life of
cell-products compared to protein or viral based products.
However, a stem cell laboratory may benefit from the use
of robotics and other automated procedures (entailing
protocol standardization, decreased variability, and time
effort) that may evoke other measurement needs such as
developing and then applying to routine manufacture assays for assessing quality of cells, stem cell markers, differentiation status, and abnormal growth properties.
Single-use bioreactor technology is becoming increasingly popular for cell cultures and it provides an
1525
Biotechnology
Journal
Biotechnol. J. 2012, 7, 1522–1529
www.biotechnology-journal.com
Table 3. Industrial needs for M3C methodologies in cell culture technology
Need
Examples
Impact
Robust easy-to-use small sensors
Exploiting progress in nano- and microchip
fabrication for cell culture parameters
Facilitating at-line process monitoring
Identify critical quality attributes
Specification of the QbD control space at
the upstream stages of the process
Accomplishment of regulatory PAT initiative
objectives
Basic sensors for bioreactors
Sensors for pH, pO2 and CO2 that cope with
new construction materials, that manage with
γ-ray sterilization
Strengthen new disposable or single-use
designs
Disposable multichip-based sensors
Sensors tailored for a limited number of CQA
Easy-use, low need for experts,
low cost for at-line monitoring
Systems biotechnology models that
support cell and process engineering
Detailed mechanistic and metabolic flux models
constrained by exometabolomics
Monitoring and control of processes under
production conditions; Metabolic engineering of producer cell lines
Scaled-down models of the
whole process sequence
Up- and downstream process development.
Computational fluid dynamics
Trouble-shooting and improvement of
existing commercial scale processes
Mapping glycoprotein pattern
Capillary electrophoresis and capillary gel
electrophoresis with laser induced fluorescence
Quality control, optimization of titer of key
product glycoforms, cell clone selection
Spectrometry methods using
MVDA for defined applications
2D fluorimetry for cell growth and product
quantity analysis
Online monitoring of culture performance
Speed-up expression array methods
Reduce/tailor the number of target genes per array Decision-making
Methods for on-line gene
vector monitoring
Monitoring adenovirus vector production
Optimization of vector production process
On-line glycoprotein monitoring
in downstream processing
Monitoring of chromatographic column steps
Increased final product quality
Platform for collection of
software programs
The same computer tool operates simultaneously Matlab™, DoE software, CAD-software
Would make exploitation and use of
modeling methods and data doable in
industrial environments and could even
impact automatic control
Stem cell expansion biomarker
(e.g., immunosensors)
Adapted to specific cell types
Increase quality of stem cell manufacturing
opportunity for the production of cells for patientspecific therapies and toxicological studies. However,
single-use technology introduces new demands. Polymeric construction materials may lead to new unexpected effects. The stability and sensitivity of traditional measurement and monitoring methods need to be
evaluated in this new environment while single-use
sensors capable of withstanding γ-radiation sterilization must be developed.
M3C activities in the subsequent downstream processing operations are often disregarded in favor of upstream operations.
When it comes to modeling, mechanistic and hybrid
models should ideally be integrated with the upstream
process operations. The use of mechanistic models integrating sequential purification steps has enabled troubleshooting in the downstream process in real-time [33].
Non-mechanistic models or black box models may
also be of great value. MVDA in different forms (PLS,
ANN, hybrid structures) appears to be acceptable if properly verified.
1526
PAT aims at gaining better process understanding.
This understanding also includes factors that can be efficiently measured, monitored, and controlled. Relevant at-
Figure 2. Need triangle illustrating the increasing demand for M3C when
going from protein to cell production.
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Biotechnol. J. 2012, 7, 1522–1529
www.biotecvisions.com
tributes, however, are often not sufficiently identified yet.
Furthermore, some attributes can only be improved by
cell line engineering while others, such as overflow metabolism, can be improved with on-line monitoring and
control.
The lack of reliable PAT tools is largely due to the complexity of the biomolecular and cellular structures (Fig. 2).
Identification of CQAs and product characterization
should bear this in mind when searching for new M3C applications.
5 What in modern S&T would best
solve these industrial needs?
Today’s state-of-the-art in M3C has the potential to solve
several of the abovementioned industrial needs. A key
message is that there are opportunities for a more efficient utilization of existing technologies, and a transfer of
new methodologies being established in academia to
R&D and production in industry. But the M3C research
and methodologies must be targeted or driven by point of
application, e.g., application to aid process definition and
development versus process monitoring and control during routine (GMP) manufacture. If M3C are not applied
during first stages (i.e., R&D and clinical manufacturing)
then it is very unlikely that M3C get exploited for routine
commercial manufacture. Also, the M3C research community needs to understand how and why M3C tools are
applied in R&D and the criteria applied when they are being considered for application or exploitation in routine
GMP manufacturing (clinical or commercial).
In general, priority should be given to methods that are
simple, fast and easily integrated into the PAT concept for
measurement of product quantity and quality.
Simplification of sensor technology in terms of smaller and cheaper mass produced sensors (e.g., by printing
techniques and micro-electromechanical systems,
MEMS) is a direction of development that is both technology-driven and pulled by the application demands in
many industrial areas. Single-use integrated chip technology based on stabilized antibody/fragments is an example of this. Multi-sensor chips for medium components
or other analytes in cell culture media would provide
process engineers and QC analysts with convenient tools
in a busy plant facility/QC laboratory environment. These
devices must, however, be able to reliably measure, if not
in real-time, at least in the required time-window to enable process changes.
For intracellular states, methods allowing the characterization of cellular metabolism with, for instance, HPLC,
GC-MS, or 1H NMR methods would be able to promote detailed metabolic models and new systems biotechnology
findings.
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Original efforts are necessary to meet several of the
needs. Examples of such efforts include the use of highthroughput reversed-phase-like techniques for both upstream as well as downstream product analysis providing
responses in seconds rather than minutes. Inventive
solutions to NIR/MIR spectroscopic/fluorometric techniques for analysis of raw materials, product quality, and
formulation could also be further exploited in cell culture
technology, as they have been for other pharmaceutical
production applications [34, 35]. The access to stable fluorescent markers, such as GFP for assay development
could also be exploited further in combination with improved MVDA methods.
Innovative solutions should address analytical targets
such as determination of viral titers or the ratio of
full/empty viral particles, monitoring of population heterogeneity during long-term cultivation by single cell
analysis, and computational fluid dynamics modeling of
3D complex multiphase flows, able to predict the ranges
of shear stresses experienced by cells under specific production conditions. The data acquisition and analysis capacity has also to be adapted.
A very important issue is the education and training
in using the M3C methods. Several of the methods require
substantial skills and experience such as data mining and
handling of spectral information. New analytical methods
must therefore be tailored for implementation at the user
site.
6 Recommendations
(i) The PAT/QbD initiative of 2004 has evoked considerable activity worldwide in analytical research in both
chemical- and bio-pharmaceutical development. For the
latter, animal and human cell culture processes have an
increasing share. It is therefore recommended that research efforts in analytical technology should address
these needs.
(ii) Cell cultures have a number of unique properties
that need to be analyzed with higher resolution if the analytical information is to be of value for automation and
control. These include product glycosylation, critical intracellular variables, virus titers, and vector integrity as
well as starting materials and medium components. Research on new M3 methods should focus on these analytical needs.
(iii) Both data-based and mechanistic models are able
to meet specific industrial needs in cell culture technology. Soft sensors based on on-line signals could use regression models or models based on advanced mechanistic modeling. Models that exploit metabolomic, transcriptomic, and other omic data should therefore be further developed and information obtained better integrated to
facilitate interpretation.
1527
Biotechnology
Journal
Biotechnol. J. 2012, 7, 1522–1529
www.biotechnology-journal.com
(iv) Development of analytical technology should be
enhanced significantly. General sensor technology and
data processing methodology for industrial applications
have undergone strong development mainly targeting areas other than biochemical and cell culture engineering.
Thus, progress in e.g. nanotechnology, MEMS, microfluidics with soft lithography, screen printing, MVDA, bioinformatics, etc. could be adapted and integrated for cell
culture applications.
(v) M3C techniques should be developed toward easy
and robust operation. Several research M3C products
have been too technically demanding and have failed to
deliver solutions that can realistically function in a GMPcontrolled process environment. Even with more relaxed
regulatory requirements this boundary condition will remain. Multi-sensor approaches, such as microarray chips,
disposable low-cost sensors, and a more extensive use of
spectroscopic methods in combination with MVDA can
contribute to achieving this aim.
(vi) New M3C shall be compatible with the whole train
of validation steps, materials, single-use equipment, sterilization, and γ-radiation. In cell culture technology, this is
a more demanding task than in other biotechnology applications, because of lower titers and more sensitive cells
for which analytical data tend to have higher variability
and lesser accuracy.
(vii) Software for data management and analysis will
most certainly continue to influence M3C. Platform solutions, if possible via Internet access, where data and computation methods become interchangeable between
powerful software (e.g., Matlab, Matematica, Simca,
Modde) should be used within the M3C applications in
cell culture manufacturing and development.
(viii) A final recommendation is to encourage further
M3C research within consortia of partners including academia, tool vendors and the end-user (biotherapeutics industry), and, by that, improve the takeup of outputs by the
biotherapeutics industry.
The authors would like to thank Dr. Bo Kara, Fujifilm
Diosynth Biotechnologies, for valuable suggestions concerning use of M3C in industrial animal cell cultures.
The authors declare no conflict of interest.
7 References
[1] Schügerl, K., Bioreaction Engineering, Bioprocess Monitoring, Vol. 3,
John Wiley & Sons, Chichester, UK 1997.
[2] Sonnleitner, B., Instrumentation of biotechnological processes. Adv.
Biochem. Eng. Biotechnol. 1999, 66, 1–64.
[3] Mandenius, C. F., Recent developments in monitoring, modeling
and control of biological production systems. Bioprocess Biosyst.
Eng. 2004, 26, 347–351.
1528
[4] Teixeira, A. P., Oliveira, R., Alves, P. M., Carrondo, M. J. T., Advances
in on-line monitoring and control of mammalian cell cultures: Supporting the PAT initiative (review). Biotechnol. Adv. 2009, 27,
726–732.
[5] United States Federal Food and Drug Administration (USA), Guidance for Industry, Process Analytical Technology, FDA, 2004.
[6] European Medicines Agency, EMA-FDA pilot program for parallel
assessment of Quality by Design applications. Document
EMA/172347/2011, 2011.
[7] International conference on Harmonization (ICH) Document ICH
Q1–Q11, 2005–2011. Available at www.ich.org.
[8] Glassey, J., Gernaey, K. V., Oliveira, R., Striedner, G. et al., PAT for
biopharmaceuticals. Biotechnol. J. 2011, 6, 369–377.
[9] Mandenius, C. F., Graumann, K., Schultz, T. W., Premsteller, A. et al.,
Quality-by-Design (QbD) for biotechnology-related pharmaceuticals. Biotechnol. J. 2009, 4, 600–609.
[10] Baradez, M. O., Marshall, D., The use of multidimensional imagebased analysis to accurately monitor cell growth in 3D bioreactor
culture. PLoS One 2011, 6, e26104.
[11] Burgemeister, S., Nattkemper, T. W., Noll, T., Hoffrogge, R., Flaschel,
E., CellViCAM – Cell viability classification for animal cell cultures
using dark field micrographs. J. Biotechnol. 2010, 149, 310–316.
[12] Ernst, W., Trummer, E., Mead, J., Bessant, C. et al., Evaluation of a
genomics platform for cross-species transcriptome analysis of recombinant CHO cells. Biotechnol. J. 2006, 1, 639–650.
[13] Becker, J., Hackl, M., Jakobi, T., Rupp, O. et al., Unraveling the
Chinese hamster ovary cell line transcriptome by next-generation
sequencing. J. Biotechnol. 2011, 156, 227–235.
[14] Schulze-Horsel, J., Genzel, Y., Reichl, U., Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production. BMC Biotechnol. 2008, 8, 45.
[15] Serra, M., Brito, C., Correia, C., Alves, P. M., Process engineering
human pluripotent stem cells for clinical applications. Trends
Biotechnol. 2012, 30, 350–359.
[16] Schwarzer, J., Rapp, E., Henniga, R., Genzel Y. et al., Glycan analysis in cell culture-based influenza vaccine production: Influence of
host cell line and virus strain on the glycosylation pattern of viral
hemagglutinin. Vaccine 2009, 27, 4325–4336.
[17] Ritter, J. B., Wahl, A. S., Freund, S., Genzel, Y., Reichl, U., Metabolic
effects of influenza virus infection in cultured animal cells: Intra- and
extracellular metabolite profiling. BMC Syst. Biol. 2010, 4, 61.
[18] Volmer, M., Northoff, S., Scholz, S., Thüte, T. et al., Fast filtration for
metabolome sampling of suspended animal cells, Biotechnol. Lett.
2011, 33, 495–502.
[19] Hansen, S. K., Skibsted, E., Staby, A., Hubbuch, J., A label-free
methodology for selective protein quantification by means of
absorption measurements. Biotechnol. Bioeng. 2011, 108,
2661–2669.
[20] Mandenius, C. F., Andersson, T. B., Alves, P. M., Batzl-Hartmann, C.
et al., Towards preclinical predictive drug testing for metabolism
and hepatotoxicity by in vitro models derived from human embryonic stem cells: A report on the Vitrocellomics EU-project. Altern.
Lab. Anim. 2011, 39, 147–171.
[21] Kreij, K., Mandenius, C. F., Clemente, J. J., Cunha, A. E. et al.,
On-line detection of microbial contaminations in animal cell reactor
cultures using an electronic nose device. Cytotechnology 2005, 48,
41–58.
[22] Aehle, M., Kuprijanov, A., Schaepe, S., Simutis, R., Lübbert, A., Simplified off-gas analyses in animal cell cultures for process monitoring
and control purposes. Biotechnol. Lett. 2011, 33, 2103–2110.
[23] Kacmar, J., Srienc, F., Dynamics of single cell property distributions in Chinese hamster ovary cell cultures monitored and controlled with automated flow cytometry. J. Biotechnol. 2005, 120,
410–420.
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Biotechnol. J. 2012, 7, 1522–1529
www.biotecvisions.com
[24] Teixeira, A. P., Duarte, T. M., Carrondo, M. J. T., Alves, P. M.,
Synchronous fluorescence spectroscopy as a novel tool to enable
PAT applications in bioprocesses. Biotechnol. Bioeng. 2011, 108,
1852–1861.
[25] Landgrebe, D., Haake, C., Höpfner, T., Beutel, S. et al., On-line
infrared spectroscopy for bioprocess monitoring (review). Appl.
Microbiol. Biotechnol. 2010, 88, 11–22.
[26] Luttmann, R., Bracewell, D. G., Cornelissen, G., Gernaey, K. V. et al.,
Soft sensors in bioprocesses: Status report and recommendation.
Biotechnol. J. 2012, 7, 1040–1048.
[27] Carinhas, N., Bernal, V., Teixeira, A. P, Carrondo, M. J. T et al., Hybrid
metabolic flux analysis: Combining stoichiometric and statistical
constraints to model the formation of complex recombinant products. BMC Syst. Biol. 2011, 5, 34.
[28] Teixeira, A. P., Alves, C., Alves, P. M., Carrondo, M. J. T., Oliveira R.,
Hybrid elementary flux analysis/nonparametric modeling: Application for bioprocess control. BMC Bioinf. 2007, 8, 30.
[29] Rathore, A. S., Mhatre, R. (Eds.), Quality by Design for Biopharmaceuticals: Principles and Case Studies, Wiley and Sons Inc., New
York 2009.
© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
[30] Lienqueo, M. E., Mahn, A., Salgado, J. C., Shene, C., Review: Mathematical modeling of Protein Chromatograms. Chem. Eng. Technol.
2012, 35, 46–57.
[31] Kirouac, D. C., Zandstra, P. W., The systematic production of cells for
cell therapy (review). Cell Stem Cell 2008, 3, 370–381.
[32] Thomas, R. J., Hourd, P. C., Williams, D. J., Application of process
quality engineering techniques to improve the understanding of the
in vitro processing of stem cells for therapeutic use. J. Biotechnol.
2008, 136, 148–155.
[33] Susanto, A., Knieps-Grünhagen, E., von Lieres, E., Hubbuch, J.,
High throughput screening for the design and optimization of
chromatographic processes: Assessment of model parameter determination from high throughput compatible data. Chem. Eng. Technol. 2008, 31, 1846–1855.
[34] Luypaert, J., Massart, D. L., Van der Heyden, Y., Review: Near-Infrared
spectroscopy in pharmaceutical analysis. Talanta 2007, 72, 865–883.
[35] Lee, H. W., Christie, A., Liu, J. J., Yoon, S., Estimation of raw material performance in mammalian cell culture using near infrared spectra combined with chemometrics approaches. Biotechnol. Prog.
2012, 28, 824–832.
1529